While only melanoma cells bearing the BRAF V600E mutation responded in our assays to pyridinyl imidazole compounds by ERK signaling inhibition, the cellular vacuolization, and delocalization of mTOR kinase was observed in both NRAS- and BRAF-mutant cells. This evidence concerns the gene BRAF and melanoma.